<DOC>
	<DOC>NCT00103831</DOC>
	<brief_summary>A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.</brief_summary>
	<brief_title>Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Advanced or metastatic pretreated NSCLC Measurable disease Adequate hematologic, hepatic and renal functions. ECOG Performance Status 02 Inability to swallow capsules Recent significant cardiovascular disease Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>NSCLC - non-small cell lung cancer</keyword>
</DOC>